the β-cell mass and provide improved treatments for T1D and T2D subjects. Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gastrointestinal L cells in response to food ingestion, and has been currently used for the treatment of T2
Search Results
Wenjuan Liu, Harry Kevin Lau, Dong Ok Son, Tianru Jin, Yehong Yang, Zhaoyun Zhang, Yiming Li, Gerald J Prud’homme, and Qinghua Wang
Benjamin J Lamont and Sofianos Andrikopoulos
Introduction The incretins glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) act via specific G-protein-coupled receptors to potentiate insulin secretion from pancreatic β-cells in a glucose-dependent manner
Shin Tsunekawa, Naoki Yamamoto, Katsura Tsukamoto, Yuji Itoh, Yukiko Kaneko, Toshihide Kimura, Yoh Ariyoshi, Yoshitaka Miura, Yutaka Oiso, and Ichiro Niki
Introduction The beneficial effects of glucagon-like peptide 1 (GLP-1) and its related substances such as inhibitors of dipeptidyl peptidase IV, its degrading enzyme, on the pancreatic β-cells have been reported; these agents enhance
João Paulo G Camporez, Mohamed Asrih, Dongyan Zhang, Mario Kahn, Varman T Samuel, Michael J Jurczak, and François R Jornayvaz
., Yellow Springs, OH, USA). Plasma fatty acids were determined with the NEFA C Kit (Wako Pure Chemical Industries, Osaka, Japan). Plasma insulin, glucagon, and adiponectin were measured by RIA Kits (Millipore, Billerica, MA, USA). For glucagon measurements
E N Fazio, M Everest, R Colman, R Wang, and C L Pin
.1% Triton X-100) then incubated for 1 h with primary antibodies, including rabbit anti-amylase (1:1000; Calbiochem), mouse anti-insulin (1:500; Sigma), rabbit anti-glucagon (1:100; Sigma), rabbit anti-pdx1 (1:1000; a generous gift from Dr C. Wright
Berit Svendsen, Ramona Pais, Maja S Engelstoft, Nikolay B Milev, Paul Richards, Charlotte B Christiansen, Kristoffer L Egerod, Signe M Jensen, Abdella M Habib, Fiona M Gribble, Thue W Schwartz, Frank Reimann, and Jens J Holst
Introduction The incretin hormones, glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) strongly potentiate postprandial insulin secretion and are therefore important regulators of glucose homeostasis. They are
C Y Shan, J H Yang, Y Kong, X Y Wang, M Y Zheng, Y G Xu, Y Wang, H Z Ren, B C Chang, and L M Chen
to affect host metabolism and energy storage ( Ley et al . 2006 ) and to affect gut permeability and, as a consequence, give rise to metabolic endotoxemia and higher plasma lipopolysaccharide (LPS). In addition, gut peptides such as glucagon
Akiko Mizokami, Satoru Mukai, Jing Gao, Tomoyo Kawakubo-Yasukochi, Takahito Otani, Hiroshi Takeuchi, Eijiro Jimi, and Masato Hirata
et al. 2014 ) or indirectly through stimulation of the secretion of glucagon-like peptide-1 (GLP-1) from intestinal endocrine cells ( Mizokami et al. 2013 , 2014 ). GLP-1 is a member of the incretin family of hormones that are secreted from
Srilaxmi Kalavalapalli, Fernando Bril, Joy Guingab, Ariana Vergara, Timothy J Garrett, Nishanth E Sunny, and Kenneth Cusi
under investigation for NASH, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown a significant promise for the treatment of NAFLD ( Ding et al. 2006 , Blonde & Russell-Jones 2009 , Cusi 2012 , Armstrong et al. 2013 , 2016 a , b
Helena A Walz, Linda Härndahl, Nils Wierup, Emilia Zmuda-Trzebiatowska, Fredrik Svennelid, Vincent C Manganiello, Thorkil Ploug, Frank Sundler, Eva Degerman, Bo Ahrén, and Lena Stenson Holst
Introduction Intracellular cAMP is crucial for pancreatic β-cell function. Insulin secretion stimulated by glucagon and incretin hormones, e.g. glucagon-like peptide-1 (GLP-1), is exerted via increased cAMP ( Gromada et al. 1998
